Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Abbott Laboratories and Galapagos are joining to develop GLPG0634, an oral Janus kinase 1 inhibitor in Phase II development at Galapagos for the treatment of autoimmune diseases such as rheumatoid arthritis. Abbott will make an initial payment of $150 million to Galapagos. Upon successful completion of Phase II studies, Abbott will license the program for a one-time fee of $200 million and will take on full responsibility for Phase III trials. Additional milestone payments to Galapagos could amount to $1 billion.
This article has been sent to the following recipient: